Does administration of hydroxychloroquine/amiodarone affect the efficacy of enzyme replacement therapy for Fabry mice?

Does administration of hydroxychloroquine/amiodarone affect the efficacy of enzyme replacement therapy for Fabry mice?

As a standard therapy for Fabry disease, enzyme replacement therapy (ERT) with recombinant human α-galactosidase A (α-Gal) has been successfully used, and the instructions for this drug state that “it should not be co-administrated with cationic amphiphilic drugs such as hydroxychloroquine (HCQ) and...

Full description

Bibliographic Details
Main Authors: Takahiro Tsukimura, Koki Saito, Tomoko Shiga, Yasuhiro Ogawa, Hitoshi Sakuraba, Tadayasu Togawa
Format: Article
Language:English
Published: Elsevier 2024-06-01
Series:Molecular Genetics and Metabolism Reports
Subjects:
Fabry disease
Drug-induced phospholipidosis
Cationic amphiphilic drug
Hydroxychloroquine
Amiodarone
Enzyme replacement therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2214426924000326

Similar Items

Similar Items